Tag: ASCVD

Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program

The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for treatment of atherosclerotic cardiovascular disease and potentially other conditions OXFORD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and […]

Desert Oasis Healthcare Offers Eligible Members Digital Cardiovascular Coaching Program Through Lark Health

PALM SPRINGS, Calif. and MOUNTAIN VIEW, Calif., March 31, 2022 /PRNewswire/ — Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, and Lark Health today announced that DOHC will offer Lark Heart Health, a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease (ASCVD) and coronary artery disease (CAD). Together, DOHC and Lark will study the innovative program as […]

Lark Health Builds AI-Driven Heart Health Program

New Program Will Provide Real-Time Coaching to Support the Prevention and Management of Atherosclerotic Cardiovascular Disease and Coronary Artery Disease  MOUNTAIN VIEW, Calif., March 16, 2022 /PRNewswire/ — Lark Health today announced the development of a novel AI-driven program for the prevention and management of atherosclerotic cardiovascular disease (ASCVD) and coronary artery disease (CAD) in collaboration with Roche Diagnostics. The program, […]

NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)

Study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, as an adjunct to diet and maximally tolerated lipid-lowering therapy Company is expected to complete enrollment in 2022 and announce data in the first quarter of 2024 NAARDEN, Netherlands–(BUSINESS WIRE)–NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies […]

Cerner and Duke Clinical Research Institute Collaborate on Cardiac Risk App

KANSAS CITY, Mo., Aug. 23, 2018 (GLOBE NEWSWIRE) — Cerner, a global leader in health care technology, collaborated with Duke Clinical Research Institute to develop an atherosclerotic cardiovascular disease (ASCVD) Risk Calculator app, designed as a tool to increase communication between the person and their doctor about ways to live a healthier life and risk […]